论文部分内容阅读
胆管癌相关抗原（ＣＣＲＡ）是我们从人胆管癌组织中提取的一种新的肿瘤标志物。建立了检测ＣＣＲＡ的ＥＬＩＳＡ方法，检测了４０例正常人及２６８例良恶性疾病病人血清的ＣＣＲＡ浓度，后者包括胆管癌３６例、原发性肝癌４０例、胰腺癌２６例、胃癌３１例、结直肠癌３４例、肺癌１７例、肝硬变２０例、胆石症４０例及胃溃疡２４例。结果显示：４０例正常对照组的血清ＣＣＲＡ浓度为（１４．３８±７．３４）μｇ／ｍｌ（ｘ±ｓ），正常上限为２８．９５μｇ／ｍｌ（ｘ＋２ｓ）；血清ＣＣＲＡ诊断胆管癌的敏感性是７７．７８％，明显高于其它肿瘤组（０～２５）％（Ｐ＜０．００１），特异性是（７５～１００）％。认为对于胆管癌的诊断，ＣＣＲＡ可能是一种较特异的肿瘤相关抗原。
The cholangiocarcinoma-associated antigen (CCRA) is a new tumor marker that we extracted from human cholangiocarcinoma tissue. An ELISA method for the detection of CCRA was established to detect the serum CCRA concentrations in 40 normal subjects and 268 patients with benign and malignant diseases. The latter included 36 cases of cholangiocarcinoma, 40 cases of primary liver cancer, 26 cases of pancreatic cancer, and 31 cases of gastric cancer. There were 34 cases of colorectal cancer, 17 cases of lung cancer, 20 cases of liver cirrhosis, 40 cases of cholelithiasis, and 24 cases of gastric ulcer. The results showed that the serum CCRA concentration in 40 normal controls was (14.38±7.34)μg/ml (x±s), the upper limit of normal was 28.95 μg/ml (x+2s); the sensitivity of serum CCRA in the diagnosis of cholangiocarcinoma The sex was 77.78%, which was significantly higher than other tumor groups (0-25)% (P<0.001) and specificity was (75-100)%. It is believed that CCRA may be a more specific tumor-associated antigen for the diagnosis of cholangiocarcinoma.